IPCA LABS LTD
GenericsIPCA LABS LTD is a generic drug manufacturer focused on Cardiovascular, Neurology, Gastroenterology.
IPCA LABS LTD at a Glance
- Strong track record with 100% execution quality across 29 trials
- Fast trial execution (2 months median completion)
IPCA LABS LTD's Key Drugs
IPCA LABS LTD's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
IPCA LABS LTD's Recent FDA Approvals
New NDA/BLA approvals for IPCA LABS LTD over the last two years — novel drugs only, excluding generics and label supplements.
IPCA LABS LTD's Therapeutic Areas
IPCA LABS LTD's approved drugs and pipeline span 4 therapeutic areas, led by Cardiovascular and Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
IPCA LABS LTD's Top Competitors
IPCA LABS LTD's closest competitors by therapeutic-area and drug-target overlap include WARNER CHILCOTT, Bristol-Myers Squibb, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
IPCA LABS LTD Pipeline Snapshot
Active clinical trials for IPCA LABS LTD across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/0 completed
- • Speed: 2 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2006-09-18
- Latest
- 2026-06-18
- Applications
- 33
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges